

K_v1.5 Potassium Channel Assay Using the IonWorks HT System

IONWORKS HT APPLICATION NOTE #1





By James Costantin, Ph.D., Andrew Wittel and Wilhelm Lachnit, Ph.D., Molecular Devices, 1311 Orleans Dr., Sunnyvale, CA 94089.

INTRODUCTION

Ionic currents that pass through ion channels are responsible for maintaining and modifying the membrane potential within animal cells from prokaryotes to complex eukaryotes. Voltagedependent ion channels are especially important in higher animals in the control of cardiac and neuronal activity. Voltage clamp techniques, developed over 40 years ago, allow direct control of the membrane potential inside very large (molluscan) nerve cells and a direct measurement of ionic currents through ion channels. The patch clamp technique (Figure 1a), introduced in 1981, is a refinement of voltage clamp techniques and allows the experimenter to measure ionic currents in much smaller cells, including mammalian cells.1 Conventional

methods of this technique require equipment from multiple vendors and a high degree of technical skill to perform, and are time and labor intensive. Furthermore, this technique does not have the capacity to be significantly automated and scaled-up. The planar patch clamp technique (Figure 1b), using a flat substrate with a hole, reduces some of the technical difficulties. Specifically, the construction of patch pipettes, the use of a microscope and micromanipulators to position the pipettes to the cell, and the need for a vibration isolation table are all eliminated. The planar patch technique also provides the opportunity to scale up the experimental throughput by performing multiple recordings in parallel. The IonWorks® HT System greatly improves throughput by using the PatchPlate™, a 384-well substrate. Parallel recordings are performed by the use of the 48-channel electronic headstage.





This application note describes the use of the IonWorks HT Platform with a voltage-dependent potassium channel $K_v 1.5.^2$ Voltage-dependent potassium (K_v) channels control the repolarization of action potential waveforms and the patterns of neuronal firing by opening and closing in response to the dynamic voltages present across the cell membrane. $K_v 1.5$ channels are of the delayed rectifier type, meaning that they have slower activation kinetics and very little inactivation when compared to other K_v channels. They are a widely studied channel and a candidate for drug discovery as a target of anti-arrhythmic drugs.

 K^+ channels can be divided into two main families based on the structure of their individual pore-forming subunits. K_{ν} channels are a subset of the family with six transmembrane spanning domains (Figure 2); inward rectifiers are the other family with only two transmembrane


domains. K_v 1.1 to K_v 1.9 are a subset of K_v channels with the most homology to the Shaker potassium channel. A functional K_v channel requires four individual pore-forming subunits (Figure 2) while a functional inward rectifier requires a varied stoichiometry of heterologous subunits. The pore-forming or α subunit of K_v channels includes an intrinsic voltage sensor, a K^+ selectivity filter, as well as activation and inactivation gates.


BACKGROUND

 $\rm K_v 1.5$ channels were expressed in Chinese hamster ovary (CHO) cells. Ionic currents were recorded on the IonWorks HT Instrument and compared with currents recorded using conventional patch clamp techniques. A comparison of the inhibition of $\rm K_v 1.5$ channel currents by 4-Aminopyridine (4-AP) was also performed using the IonWorks HT Instrument and conventional patch clamp techniques.

MATERIALS

- \rightarrow Cells: Chinese hamster ovary (CHO) cells expressing the $K_v 1.5$ potassium channel
- → Reagents and buffers: 4-Aminopyridine
 (4-AP) (Sigma Cat. # A0152), Amphotericin
 (Sigma Cat. # A-4888), DMSO (Sigma
 Cat. # D-2650) were used. Internal Buffer:
 high K⁺, low Cl⁻ internal buffer containing
 (in mM): 100 K-Gluconate (Sigma Cat. #
 G-4500, 40 KCl (Sigma Cat. # P-9333),
 3.2 MgCl₂ (Sigma Cat. # M-2670),
 5.0 EGTA (Sigma Cat. # E-0396), 5.0 Hepes
 (Sigma Cat. # H-7523) pH 7.25 with KOH.
 External Buffer: Phosphate Buffered Saline
 (PBS, Gibco Cat. # 14040)
- → Tissue culture flasks: Cells were grown in T-75 flasks (Corning Cat. # 430641)
- → Cell culture media: Ham's F-12 (Irvine Cat. # 9058), fetal bovine serum (FBS, Irvine Cat. # 3000), Glutamine/Penicillin/Streptomycin





(G/P/S) (Irvine Cat. # 9316), Geneticin (G-418, Gibco Cat. # 10131) to grow the cells; Versene[™] (Gibco Cat. # 15050) was used to remove the cells from the flasks

- → PatchPlates: Molecular Devices Cat. # 9000-0688
- → Compound plates: Costar® 96-well plate Cat. # 3355

METHODS

Cell culture

CHO cells were grown in F-12 media supplemented with 10% fetal calf serum, G/P/S (1%) and G-418 (1%) as a selection antibiotic. Cells were plated at a density of ~1-3 x 10⁶ cells/ml and passaged at regular intervals when the flasks reached 80-100% confluence. To prepare the cells for experimental runs, they were passaged at 1:4 to 1:10 (flasks) 3-5 days prior to their use on the instrument.

Preparation of antibiotic solution

Aliquots of amphotericin (5 mg) were preweighed and stored at 4°C. Prior to cell preparation, 180 µL of DMSO was added to an aliquot of amphotericin. Amphotericin/DMSO solution was vortexed until clear (-2 minutes) and then added to 50 ml of Internal Buffer and vortexed for -1 minute. Solution was placed in the dark until ready to use.

Cell preparation procedure

Note: This step should be performed after the preparation of all other reagents.

Step 1: Cells (80-95% confluence) were removed from the incubator 3-5 days after being plated.

Step 2: Growth media was removed from the culture flasks and cells were gently rinsed with 4 ml Versene solution for less than 10 seconds, then the solution was removed.


Step 3: 4 ml of Versene solution was added and cells incubated for 6-9 minutes (at 37°C) until cells rounded up and could be easily dislodged from the bottom of the flask with a few brief raps on a solid surface. 20 ml of PBS was added to the flask and the cell suspension was added to two 15 ml tubes (divided equally).

Step 4: The 15 ml tubes were spun down at 800 rpm in a table-top centrifuge. Supernatant was removed and 2.5-3 ml PBS was added per tube and vigorously triturated.

Step 5: A single tube (2.5-3.0 ml) of cell suspension was added to a cell boat on the IonWorks HT Instrument just prior to beginning the experimental run.

Preparation of compound plate

A 105 mM stock solution of 4-AP was prepared in 1% DMSO. This was diluted 1:3 in PBS and 390 μ L of the resulting 35 mM solution



consists of over 250 data points with individual data points obtained from separate

cells (< 45 minutes/run, mean ± SEM).

Compound Plate Preparation (Figure 5)

1	2	3	4	5	6	7	8	9	10	11	12
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
3.5E-2	1.2E-2	3.9E-3	1.3E-3	4.3E-4	1.4E-4	4.8E-5	1.6E-5	5.3E-6	1.8E-6	3.5E-2	0
	3.5E-2 3.5E-2 3.5E-2 3.5E-2 3.5E-2 3.5E-2	3.5E-2 1.2E-2 3.5E-2 1.2E-2 3.5E-2 1.2E-2 3.5E-2 1.2E-2 3.5E-2 1.2E-2 3.5E-2 1.2E-2	3.5E-2 1.2E-2 3.9E-3	3.5E-2 1.2E-2 3.9E-3 1.3E-3	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6	3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2 3.5E-2 1.2E-2 3.9E-3 1.3E-3 4.3E-4 1.4E-4 4.8E-5 1.6E-5 5.3E-6 1.8E-6 3.5E-2

Values in table are [4-AP] in M.

was added to each of the wells in column 1 and column 11 of the compound plate. 260 µL of PBS was then added to columns 2-10 and 12. 130 µL of solution was then simultaneously aspirated out of each of the wells in column 1, dispensed into column 2, and subsequently mixed ten times using the pipettor. This procedure was repeated, transferring 130 µL of solution from column 2 to 3, 3 to 4, etc. through column 10. The pipette tips were replaced after each mixing step. The resulting layout of the compound plate is shown in Figures 5 and 8. The concentrations will be diluted 3-fold on the instrument by the addition of 3.5 µL of compound stock to 7 µL of the buffer/cell solutions in the PatchPlate.

Electrophysiology

K_v1.5 currents were elicited by a voltage step from the holding potential of -70 mV to +40 mV for 100 ms. A modified P/N subtraction3 was used whereby a linear leak current is estimated by applying a voltage step from -70 to -80 mV. The values from this measurement are then used to extrapolate a leak I/V curve over the entire voltage range. Leak current values are then estimated from this I/V curve and subtracted digitally from all current recordings. There is no subtraction of the capacitive transients as in traditional P/N subtraction. 4-AP was incubated for 180 to 229 seconds. Similar protocols were used for the conventional patch clamp recordings with leak subtraction disabled. Pipettes were pulled from TW-150 glass (WPI) with tip sizes ranging between 3-5 M Ω . Bath perfusion of compound (180-240 seconds) was used on the conventional patch clamp setup. A PC-505 amplifier (Warner) was used in all conventional experiments.

IC₅₀ curve generation


Concentration-response curves for 4-AP were fitted to a four-parameter logistic equation:


% of control = 100 (1 +
$$([4-AP]/IC_{50})^p)^{-1}$$

where IC_{50} is the concentration of 4-AP required to inhibit current by 50% and p is the Hill slope.

RESULTS

IC₅₀ curves for 4-AP were obtained on the IonWorks HT Instrument to compare reproducibility across different experimental runs and within experimental runs. These data were also compared to that obtained using conventional patch clamp techniques. Curves were generated using cells that received solution from all of the wells of the compound plate





Sixteen IC₅₀ curves obtained from two runs. Eight individual 10-point curves/run, from eight compound plate rows. All concentrations for each curve are from a maximum of four replicates or eight replicates for highest concentration (< 45 minutes/run).

(n = max. of 32 cells/concentration) or from a subset of a single row of the compound plate (n = max. of 4 cells/concentration).


Raw current tracings are shown in Figure 3 before and after the addition of "mock" compound (negative control) and before and after the addition of 3.9 mM 4-AP. The negative controls are located on the PatchPlate where the fluidics head dispenses solution from column 12 of the compound plate. IC₅₀ curves generated from individual runs on the IonWorks HT Instrument are shown in Figure 4. Each graph is collected from a single 45-minute run and is constructed from recordings of over 250 cells in each run. The number of possible cells used for each data point is 32, except for the highest concentration of compound where the number is 64. Figure 6 shows two sets of eight IC₅₀ curves, each generated from an individual run. Each of the eight IC₅₀ curves shown in the two plots is constructed from wells on the PatchPlate that

received compound from an individual row of the compound plate. The number of possible cells used for each data point is four, except for the highest concentration of compound where the number is eight. The value for the IC_{50} curves obtained in each row are shown in Figure 6, the mean and standard deviation is also shown for all eight curves from a single 45-minute run.

Conventional patch clamp recordings were performed to compare the results obtained using the IonWorks HT Instrument. Raw data traces are shown in Figure 7 (Panel A) prior to the addition of 4-AP and also in the presence of 6 mM 4-AP. IC₅₀ curves were generated using the conventional patch clamp technique (Figure 7, Panel B). The mean value obtained for the IC₅₀ for 4-AP using the conventional technique was .773 mM (± .244).

Figure 8 shows the data display from the IonWorks HT software at the end of a run. Panel A shows

the PatchPlate view, and Panel B shows the Compound Plate view. The number shown in each compound plate well (B) is the "validcell count," i.e., the number of successful recordings obtained (out of a maximum of four replicates). The PatchPlate display uses red squares without an "X" to indicate wells that lost the seal during the experimental run. A red square with an "X" indicates that the well was filtered with a user-defined metric (in this case, due to low expression; ≤ 300 pA). Panel C is the statistical display, which tabulates the number of "no seals" and the number of cells that were filtered out with a user-defined metric. Panel D shows the "configure hits display." A comparison can be made between the user-defined metrics of two scans and differences above (or below) a certain level can be defined as a "hit."




CONCLUSIONS

The IonWorks HT Instrument delivers reliable and reproducible results in the measurement of IC₅₀ curves for 4-AP blockade of K_v1.5 channels. The results are also in agreement with the results obtained using the conventional patch clamp method. The ease in obtaining the data and the throughput of the IonWorks HT Instrument when compared to the conventional technique make it a very appealing instrument for automated high throughput electrophysiology.^{4,5}

REFERENCES

- Hamill, O.P., Marty, A., et al. (1981). Improved patch-clamp techniques for highresolution current recording from cells and cell-free membrane patches. Pflugers Arch 391(2): 85-100.
- Grissmer, S., Nguyen, A.N., et al. (1994). Pharmacological characterization of five cloned voltage-gated K⁺ channels, types

- K_v 1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. *Mol Pharmacol* 45(6): 1227-34.
- Bezanilla, F. and Armstrong, C.M. (1977). Inactivation of the sodium channel. I. Sodium current experiments. *J Gen Physiol* 70(5): 549-66.
- Kiss, L., Bennett, P. B., et al. (2003). High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay and Drug Development Technologies 1(1-2): 127-135.
- Schroeder, K., Neagle, B., et al. (2003). Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 8(1): 50-64.





SALES OFFICES

United States & Canada

Molecular Devices Tel. +1-800-635-5577

Fax +1-408-747-3601

China

Molecular Devices Brazil Tel. +55-11-3616-6607

Fax +55-11-3616-6607

Molecular Devices Beijing Tel. +86-10-6410-8669 Fax +86-10-6410-8601

Molecular Devices Shanghai Tel. +86-21-6887-8820 Fax +86-21-6887-8890

Molecular Devices GmbH Tel. +49-89/96-05-88-0 Fax +49-89/9-62-02-34-5

Molecular Devices Japan, Osaka

Tel. +81-6-6399-8211 Fax +81-6-6399-8212

Molecular Devices Japan, Tokyo

Tel. +81-3-5282-5261 Fax +81-3-5282-5262

South Korea

Molecular Devices Korea, LLC Tel. +82-2-3471-9531 Fax +82-2-3471-9532

United Kingdom

Molecular Devices Ltd. Tel. +44-118-944-8000 Fax +44-118-944-8001

www.moleculardevices.com